Abstract: Objective To investigate the therapeutic effect， long term survival and side effects on small cell lung cancer（SCLC） patients treated with lobaplatin combined with etoposide. Methods Eighty-five patients with extensivestage SCLC were retrospectively analyzed. Among these patients， 85 patients were assigned to EL group（etoposide 80 mg／m²， d1-d5+lobaplatin 30 mg／m²， d₁； 21 days as a cycle； n=42） and EP group（etoposide 80 mg／m²， d1-d5+cisplatin 25 mg／m²， d₁-d₃； 21 days as a cycle； n=43）. Efficacy and toxicities were evaluated after 2 or more cycles.
ResultsThe overall response rate were 59.5％ and 53.5％， and the disease control rate were 80.9％ and 76.7％ in EL group and EP group without significant difference（P＞0.05）. The median progression free survival of EL group was 6.5 months， higher than 4.5 months in EP group with significant difference（P＜0.05）. There were higher incidences of thrombocytopenia but lower incidence of nausea and vomiting and liver and kidney impairment in EL group versus EP group（P＜0.05）. Conclusion Compared with the EP regimen， the EL regimen can prolong the median progression survival and reduce gastrointestinal toxicity.